Pharmaceutical News

RSS

EDIMS licenses First DataBank's National Drug Data File Plus database

First DataBank, a leading provider of drug databases that help drive patient safety, and EDIMS, a leading provider of interoperable emergency department (ED) information management systems, today announced they have licensed First DataBank's National Drug Data File (NDDF) Plus™ database to offer hospitals greater choice in trusted third-party drug database information to use and integrate with EDIMS ED electronic health record (EHR).

31 Aug 2010

Bionovo receives positive guidance for Menerba drug candidate

Bionovo, Inc. announced today that it has received positive guidance from the U.S. Food and Drug Administration (FDA) regarding the Company's Chemistry, Manufacturing and Controls (CMC) plan for its lead drug candidate Menerba.

31 Aug 2010

SCOLR Pharma signs sales support agreement with Emerson Group

SCOLR Pharma, Inc. today announced that it has signed an agreement with The Emerson Group to provide sales support for the Company's new line of extended-release nutritional and over-the-counter drug products.

31 Aug 2010

Ralphs Grocery Company to offer seasonal flu vaccine at $25

Ralphs Grocery Company is making it easy and affordable for customers to stay healthy by getting seasonal flu immunizations early.

31 Aug 2010

Using clopidogrel, PPIs increases cardiac damage risk: Study

Patients with coronary artery disease undergoing stent implantation are often prescribed the antiplatelet drug, clopidogrel. This drug prevents blood clots, but is known to have a side-effect that can cause stomach bleeding. Consequently, many users are also prescribed a proton pump inhibitor (PPI). Now, however, a meta-analysis of almost 160,000 patients carried out at the Medical University of Vienna and Wilhelminenhospital, Vienna, has shown that simultaneous use of these drugs can increase the risk of cardiac damage.

31 Aug 2010

BARDA awards $27 million contract to Achaogen for antibiotic development

The U.S. Department of Health and Human Services' Biomedical Advanced Research and Development Authority (BARDA) today awarded a contract to develop an antibiotic that could be used against possibly two types of bioterrorism as well as common infections that are becoming resistant to antibiotics.

31 Aug 2010

Over use of decongestants by women leads to preterm birth delivery: Study

A new study led by Boston University School of Public Health (BUSPH) epidemiologists has found that women who took over-the-counter decongestants during their pregnancies are less likely to give birth prematurely.

31 Aug 2010

Salix Pharmaceuticals to settle patent litigation of Novel's generic version of MOVIPREP

Salix Pharmaceuticals, Ltd. today announced that Salix and Norgine B. V. have entered into an agreement with Novel Laboratories, Inc. to settle patent litigation currently pending in the U.S. District Court for the District of New Jersey (Civil Action No. 3:08-02311 (FLW)(TJB)) regarding Novel's proposed generic version of MOVIPREP.

31 Aug 2010

Roche's MabThera continues to dwarf recently launched monoclonal antibodies: Report

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, for the treatment of non-Hodgkin's lymphoma and chronic lymphocytic leukemia, 41 percent of surveyed European hematologist-oncologists say that the favorable efficacy profile of Roche's MabThera (rituximab) is the most significant driver of their use of this brand, while 26 percent say MabThera's favorable risk-benefit profile is the most significant driver.

31 Aug 2010

Achaogen receives contract from BARDA for developing ACHN-490 antibiotic treatment

Achaogen, a biopharmaceutical company discovering and developing innovative antibiotics to treat life-threatening, multi-drug resistant (MDR) bacterial infections, today announced the award of a contract with The Biomedical Advanced Research and Development Authority (BARDA), within the Office of the Assistant Secretary for Preparedness and Response in the U.S. Department of Health and Human Services.

31 Aug 2010

FDA grants Priority Review status to Alimera Sciences' Iluvien for diabetic macular edema

Alimera Sciences, Inc.,, a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, announced today that the Company's New Drug Application (NDA) for Iluvien® (fluocinolone acetonide intravitreal insert) has been accepted for filing and granted Priority Review status by the U.S. Food and Drug Administration (FDA).

31 Aug 2010

FDA extends Prescription Drug User Fee Act date for ezogabine

GlaxoSmithKline and Valeant Pharmaceuticals International announced today the U.S. Food and Drug Administration (FDA) has extended the Prescription Drug User Fee Act (PDUFA) goal date for ezogabine to 30 November 2010.

31 Aug 2010

Intendis granted rights to KYTHERA's ATX-101 candidate for minimally-invasive fat reduction outside US, Canada

KYTHERA Biopharmaceuticals, Inc. and Intendis, Bayer HealthCare's dermatology business, today announced that they have entered into a licensing agreement granting Intendis rights to KYTHERA's lead product candidate, ATX-101, outside of the US and Canada. ATX-101, a first-in-class investigational drug, is currently in clinical development for the reduction of localized fat under the chin (submental fat).

31 Aug 2010

Greater Sacramento Specialty Pharmacy acquired by The Apothecary Shops

The Apothecary Shops, a Phoenix-based chain of specialty pharmacies with 16 locations in six states, has acquired the Greater Sacramento Specialty Pharmacy (GSP), a customer-service focused pharmacy with primary specialties in oncology and pain management.

30 Aug 2010

H. D. Smith becomes primary supplier of pharmaceutical products for NAPPSA pharmacies

NAPPSA, a pharmacy buying group advancing the growing buying power of the Nigerian-owned independent retailers, today announced a new three-year prime vendor agreement with H. D. Smith, a leading national pharmaceutical wholesaler.

30 Aug 2010

Cannabis Science seeks entry into European medical cannabis market

Cannabis Science Inc., a pioneering US biotech company developing pharmaceutical cannabis products, is pleased to announce that the Company is currently raising working capital in the European market and pursuing listings on the Frankfurt and other major European exchanges.

30 Aug 2010

Perfadex improves survival in lung tranplant patients: Study

A recently published study in The Journal of Heart and Lung Transplantation shows that the patients who are most seriously ill before lung tranplantation have better one-year survival when Perfadex is used as the preservation solution for donor lungs compared with UW solution. Furthermore, the patients who received lungs preserved in Perfadex ran a significantly lower risk of being affected by rejection reactions requiring treatment.

30 Aug 2010

Nanotherapeutics files NanoDTPA IND for treatment of radiation exposure

Nanotherapeutics, Inc., announced that it has filed an Investigational New Drug (IND) Application with the Food and Drug Administration (FDA) for NanoDTPA™ an orally administered capsule that is a less invasive treatment alternative to the FDA approved injectable Zn-DTPA (diethylenetriamine pentacetic acid). DTPA is used to remove radioactive compounds from the body to help eliminate the contamination. The NanoDTPA™ capsule is a unique orally-bioavailable fine particle formulation that allows DTPA to be absorbed into the body from the gastrointestinal tract.

30 Aug 2010

Eisai receives new action date for FDA priority review of eribulin mesylate NDA for metastatic breast cancer

Eisai Inc. announced today that it has received notification from the U.S. Food and Drug Administration (FDA) that the agency expects to complete priority review of the eribulin mesylate New Drug Application (NDA) for locally advanced or metastatic breast cancer on or before December 30, 2010, which is a three month extension from the original Prescription Drug User Fee Act (PDUFA) action date of September 30, 2010.

30 Aug 2010

FDA approves additional strengths of SOLODYN for inflammatory lesions treatment

Medicis today announced that the U.S. Food and Drug Administration (FDA) has approved additional strengths of SOLODYN (minocycline HCl, USP) Extended Release Tablets in 55 mg, 80 mg and 105 mg dosages for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris in patients 12 years of age and older.

30 Aug 2010